Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. News
May 1, 2025 - globenewswire.com
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Feb 25, 2025 - businesswire.com
INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI
Intra-Cellular Therapies, Inc. Quantitative Score
About Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Intra-Cellular Therapies, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Intra-Cellular Therapies, Inc. Financials
Table Compare
Compare ITCI metrics with: | |||
|---|---|---|---|
Earnings & Growth | ITCI | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ITCI | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ITCI | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ITCI | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Intra-Cellular Therapies, Inc. Income
Intra-Cellular Therapies, Inc. Balance Sheet
Intra-Cellular Therapies, Inc. Cash Flow
Intra-Cellular Therapies, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Intra-Cellular Therapies, Inc. Executives
| Name | Role |
|---|---|
| Dr. Sharon Mates Ph.D. | Co-Founder, Chairman & Chief Executive Officer |
| Mr. Michael I. Halstead J.D. | President |
| Mr. Mark Neumann | EVice President & Chief Commercial Officer |
| Dr. Suresh K. Durgam M.D. | Executive Vice President & Chief Medical Officer |
| Mr. Sanjeev Narula | Executive Vice President, Chief Financial Officer & Treasurer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Sharon Mates Ph.D. | Co-Founder, Chairman & Chief Executive Officer | 1953 | 3.31M | |
| Mr. Michael I. Halstead J.D. | President | Male | 1973 | 1.36M |
| Mr. Mark Neumann | EVice President & Chief Commercial Officer | Male | 1964 | 1.26M |
| Dr. Suresh K. Durgam M.D. | Executive Vice President & Chief Medical Officer | 1970 | 1.21M | |
| Mr. Sanjeev Narula | Executive Vice President, Chief Financial Officer & Treasurer | Male | 1962 | 665.48K |
Intra-Cellular Therapies, Inc. Insider Trades
| Date | 2 Apr |
| Name | Salas Eduardo Rene |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 1567 |
| Date | 2 Apr |
| Name | Salas Eduardo Rene |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 20000 |
| Date | 2 Apr |
| Name | Salas Eduardo Rene |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 16757 |
| Date | 2 Apr |
| Name | Salas Eduardo Rene |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 7009 |
| Date | 2 Apr |
| Name | Salas Eduardo Rene |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 4322 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 2 Apr | Salas Eduardo Rene | Director | Disposed | D-Return | 1567 |
| 2 Apr | Salas Eduardo Rene | Director | Disposed | D-Return | 20000 |
| 2 Apr | Salas Eduardo Rene | Director | Disposed | D-Return | 16757 |
| 2 Apr | Salas Eduardo Rene | Director | Disposed | D-Return | 7009 |
| 2 Apr | Salas Eduardo Rene | Director | Disposed | D-Return | 4322 |